Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Goncagul AkdagSedat YildirimAkif DoganZeynep Yuksel YasarHamit BalOguzcan KinikogluSila OksuzUgur OzkerimSalih TunbekiciHacer Sahika YildizEzgi TurkogluOzkan AlanSermin Coban KoktenDeniz IsikOzlem Nuray SeverHatice OdabasMahmut Emre YildirimNedim TuranPublished in: Chemotherapy (2024)
Consideration of Ki67 and ER percentage aids in NAC decisions for HR+/HER2- BC, identifying patients with high NAC response rates, facilitating axillary preservation, and potentially avoiding axillary dissection. The pCR rates in patients with Ki67 ≤ 24 are particularly low, especially in patients with a high ER percentage. In these cases, upfront surgery and adjuvant treatment should be considered instead of NAC.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- sentinel lymph node
- lymph node
- locally advanced
- endoplasmic reticulum
- estrogen receptor
- breast cancer cells
- minimally invasive
- genome wide analysis
- early stage
- rectal cancer
- coronary artery bypass
- squamous cell carcinoma
- radiation therapy
- antiretroviral therapy
- acute coronary syndrome
- percutaneous coronary intervention